Cargando…

Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia

Background: Familial hypercholesterolemia (FH) is a highly prevalent disorder and a risk factor for early coronary artery disease. The objective of this registry was to document the clinical characteristics of patients with definite FH in Germany and to document lipid profiles, lipid-lowering therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Gitt, Anselm K., Laufs, Ulrich, März, Winfried, Paar, W. Dieter, Bramlage, Peter, Marx, Nikolaus, Parhofer, Klaus G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267207/
https://www.ncbi.nlm.nih.gov/pubmed/35807095
http://dx.doi.org/10.3390/jcm11133810
_version_ 1784743661856096256
author Gitt, Anselm K.
Laufs, Ulrich
März, Winfried
Paar, W. Dieter
Bramlage, Peter
Marx, Nikolaus
Parhofer, Klaus G.
author_facet Gitt, Anselm K.
Laufs, Ulrich
März, Winfried
Paar, W. Dieter
Bramlage, Peter
Marx, Nikolaus
Parhofer, Klaus G.
author_sort Gitt, Anselm K.
collection PubMed
description Background: Familial hypercholesterolemia (FH) is a highly prevalent disorder and a risk factor for early coronary artery disease. The objective of this registry was to document the clinical characteristics of patients with definite FH in Germany and to document lipid profiles, lipid-lowering therapy, and lipid target achievement during longitudinal follow-up. Methods: HYDRA-FH was a national, prospective, multicenter, non-interventional registry conducted in 35 centers in Germany. Consecutive adult patients with definite FH were included (n = 241). Results: In the cross-sectional analysis (n = 233), lipid-lowering therapy involved statins (82.0%), ezetimibe (31.8%), and PCSK9 antibodies (18.5%); 11.2% of patients were receiving no lipid-lowering drugs. Median lipid levels were: low-density lipoprotein cholesterol (LDL-C) 134 mg/dL (3.5 mmol/L), high-density lipoprotein cholesterol (HDL-C) 48 mg/dL (1.2 mmol/L), triglycerides 160 mg/dL (1.9 mmol/L), total cholesterol 211 mg/dL (5.5 mmol/L). Values were above the normal threshold (150 mg/dL) for LDL-C in 72.9%, total cholesterol in 29.7%, and triglycerides in 45.0% of patients. After the 12-month follow-up (n = 145), only 17.2% had LDL-C < 70 mg/dL, and 20.7% had either LDL-C < 70 mg/dL or a reduction of ≥50% versus baseline. Conclusion: This study provides insight into the clinical characteristics and current treatment status of patients with FH in Germany. Many patients with FH do not achieve recommended lipid levels.
format Online
Article
Text
id pubmed-9267207
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92672072022-07-09 Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia Gitt, Anselm K. Laufs, Ulrich März, Winfried Paar, W. Dieter Bramlage, Peter Marx, Nikolaus Parhofer, Klaus G. J Clin Med Article Background: Familial hypercholesterolemia (FH) is a highly prevalent disorder and a risk factor for early coronary artery disease. The objective of this registry was to document the clinical characteristics of patients with definite FH in Germany and to document lipid profiles, lipid-lowering therapy, and lipid target achievement during longitudinal follow-up. Methods: HYDRA-FH was a national, prospective, multicenter, non-interventional registry conducted in 35 centers in Germany. Consecutive adult patients with definite FH were included (n = 241). Results: In the cross-sectional analysis (n = 233), lipid-lowering therapy involved statins (82.0%), ezetimibe (31.8%), and PCSK9 antibodies (18.5%); 11.2% of patients were receiving no lipid-lowering drugs. Median lipid levels were: low-density lipoprotein cholesterol (LDL-C) 134 mg/dL (3.5 mmol/L), high-density lipoprotein cholesterol (HDL-C) 48 mg/dL (1.2 mmol/L), triglycerides 160 mg/dL (1.9 mmol/L), total cholesterol 211 mg/dL (5.5 mmol/L). Values were above the normal threshold (150 mg/dL) for LDL-C in 72.9%, total cholesterol in 29.7%, and triglycerides in 45.0% of patients. After the 12-month follow-up (n = 145), only 17.2% had LDL-C < 70 mg/dL, and 20.7% had either LDL-C < 70 mg/dL or a reduction of ≥50% versus baseline. Conclusion: This study provides insight into the clinical characteristics and current treatment status of patients with FH in Germany. Many patients with FH do not achieve recommended lipid levels. MDPI 2022-06-30 /pmc/articles/PMC9267207/ /pubmed/35807095 http://dx.doi.org/10.3390/jcm11133810 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gitt, Anselm K.
Laufs, Ulrich
März, Winfried
Paar, W. Dieter
Bramlage, Peter
Marx, Nikolaus
Parhofer, Klaus G.
Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia
title Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia
title_full Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia
title_fullStr Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia
title_full_unstemmed Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia
title_short Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia
title_sort hypercholesterolemia diagnosis, treatment patterns, and 12-month target achievement in clinical practice in germany in patients with familial hypercholesterolemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267207/
https://www.ncbi.nlm.nih.gov/pubmed/35807095
http://dx.doi.org/10.3390/jcm11133810
work_keys_str_mv AT gittanselmk hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia
AT laufsulrich hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia
AT marzwinfried hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia
AT paarwdieter hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia
AT bramlagepeter hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia
AT marxnikolaus hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia
AT parhoferklausg hypercholesterolemiadiagnosistreatmentpatternsand12monthtargetachievementinclinicalpracticeingermanyinpatientswithfamilialhypercholesterolemia